Bibliography

The CPRD bibliography is updated on a quarterly basis (last update, January 2014).

If you have published papers using the CPRD which are not included in this list, please contact us at so that we can update the bibliography.

Select a bibliography category:

  


Download Bibliography PDF or Print the Bibliography

Abstract & Posters

Select the year to view the Abstracts & Posters

Abstract & Posters - 2013

  1. An exploratory study using General Practice Research Database to compare recognition of palliative care needs for patients with heart failure compared with those with cancer
    Amy Gadoud, Eleanor Kane, Una Macleod, Miriam Johnson.
    Society for Academic Primary Care, July 2013
  2. Socio-economic position and childhood multimorbidity: a study using linkage between the Avon Longitudinal Study of Parents and Children and the General Practice Research Database
    Rosie Cornish, Andrew Boyd, Tjeerd Van Staa, Chris Salisbury, John Macleod.
    Society for Academic Primary Care, July 2013
  3. Incidence and management of Bell’s palsy in the UK: segmented time series regression analysis of treatment from 2001 to 2012
    Daniel Morales, Fergus Daly, Peter Donnan, Tjeerd van Staa, Frank Sullivan.
    Society for Academic Primary Care, July 2013
  4. Modelling conditions in the Primary Care Databases: an application to Severe Mental Illness with the Clinical Practice Research Datalink
    Ivan Olier, David Springate, David Reeves, Siobhan Reilly, Tim Doran, Evangelos Kontopantelis.
    Society for Academic Primary Care, July 2013
  5. Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using QResearch and CPRD data
    Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox
    Society for Academic Primary Care, July 2013
  6. Prevalence and Incidence of Idiopathic Pulmonary Fibrosis in UK Healthcare Databases, GPRD and THIN; Need for an IPF Registry
    Paula L Thompson, Stephanie Chretin, Francoise Bugnard, William C Maier, Rory Cameron, Mark Fisher, Christophe Giot, Christian Hill, Imran Kausar.
    Pharmacoepidemiology and Drug Safety, August 2013
  7. Is Childhood Attention-Deficit (Hyperactivity) Disorder Associated with Atopic Diseases and Skin Infections? A Matched Case-Control Study Using the GPRD
    Eelko Hak, Tjalling W De Vries, Pieter J Hoekstra, Susan S Jick.
    Pharmacoepidemiology and Drug Safety, August 2013
  8. The Identification of Incident Cancers in UK Primary Care Databases: A Systematic Review
    Michael E Rañ opa, Ian Douglas, Tjeerd van Staa, Liam Smeeth, Krishnan Bhaskaran.
    Pharmacoepidemiology and Drug Safety, August 2013
  9. Congenital Malformations in the Offspring of Women with Asthma
    Rachel Charlton, Julia Snowball, Kourtney Davis, Corinne de Vries.
    Pharmacoepidemiology and Drug Safety, August 2013
  10. Calcium Channel Blockers and Esophageal Cancer: A Case-Control Analysis
    Claudia Becker, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, August 2013
  11. Case-Control Analysis on Metformin and Cancer of the Esophagus
    Claudia Becker, Christoph R Meier, Susan S Jick, Michael Bodmer.
    Pharmacoepidemiology and Drug Safety, August 2013
  12. The Opportunities and Challenges of Delivering the Quetiapine Post-Authorization Safety Studies (PASS); a Diverse Program of Work
    Robert S Brody, Leigh Jefferies, Sherry Liu, Charles L Liss, Phil Damstetter, Lei Chen, Raj Tummala, Dhaval G Desai
    Pharmacoepidemiology and Drug Safety, August 2013
  13. Diabetes and the Risk of Incident Gout
    Saskia G Bruderer, Michael Bodmer, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, August 2013
  14. Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis
    Marloes T Bazelier, Frank de Vries, Peter Vestergaard, Ron MC Herings, Arlene M Gallagher, Hubert GM Leufkens, Tjeerd-Pieter van Staa.
    Pharmacoepidemiology and Drug Safety, August 2013
  15. Is the CPRD GOLD Population Comparable to the U.K. Population?
    Jennifer Campbell, Daniel J Dedman, Susan C Eaton, Arlene M Gallagher, Tim J Williams.
    Pharmacoepidemiology and Drug Safety, August 2013
  16. Validation of Stroke in the Clinical Practice Research Datalink (CPRD)
    Esther H Zhou, Kate Gelperin, David J Graham, Yulan Ding, Mark Levenson, Martin Rose, Shannin F Davillier, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, August 2013
  17. Design and Feasibility of a Study Using the Clinical Practice Research Datalink General Practice OnLine Database (CPRD GOLD) To Assess the Risk of Spontaneous Abortion (SA) Following Administration of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine
    Dominique Rosillon, Corinne Willame, John Logie, Sylvia Taylor, Vincent Bauchau, Maria-Genalin Angelo, Julia Zima, Judith van den Bosch, Tjeerd van Staa, Rachael Boggon, Christina Chambers, Sonia Hernandez-Diaz, Laurence Baril.
    Pharmacoepidemiology and Drug Safety, August 2013
  18. Risk of Seizures among Patients with Schizophrenia as Compared to the General Population in the Clinical Practice Research Datalink (CPRD)
    Meghan Jones, Jonathan Swain, Frank DeLisle, Ludmila Kryzhanovskaya, Bruce J Kinon.
    Pharmacoepidemiology and Drug Safety, August 2013
  19. Developing Acute Coronary Syndrome Disease Cohorts Using Primary and Secondary Care Database Linkages
    Robert N Lubwama, Cathy A Pinto.
    Pharmacoepidemiology and Drug Safety, August 2013
  20. Utilisation Patterns of Inhaled Corticosteroids in Patients with Asthma: A Study Using the UK Clinical Practice Research Datalink (CPRD)
    Alison L Nightingale, Julia Snowball, Rachel A Charlton, Corinne S de Vries.
    Pharmacoepidemiology and Drug Safety, August 2013

  1. TrialViz: A Feasibility Tool Based upon the CPRD GOLD Primary Care Database
    Tim Williams, Shivani Puri, Joss Wickson, Rosemary Tate, Natalia Beloff, Tjeerd van Staa, Adrian Bleach, John Cuthbert.
    Pharmacoepidemiology and Drug Safety, August 2013
  2. The Prescribing of Simvastatin in the UK - A Drug Utilisation Study in the Clinical Practice Research Datalink (CPRD)
    Craig Allen, Katherine L Donegan, Andrew Thomson.
    Pharmacoepidemiology and Drug Safety, August 2013
  3. Incidence of Food-Induced Anaphylaxis; a Retrospective Population Cohort Study in the UK Clinical Practice Research Datalink (CPRD)
    Estel Plana, Cristina Rebordosa, Ying Zhu.
    Pharmacoepidemiology and Drug Safety, August 2013
  4. Is the CPRD GOLD Population Comparable to the U.K. Population?
    Jennifer Campbell, Daniel J Dedman, Susan C Eaton, Arlene M Gallagher, Tim J Williams.
    Pharmacoepidemiology and Drug Safety, August 2013
  5. Defining a Denominator Population for Linked Datasets
    Shivani Puri, Tim Williams, Susan Eaton.
    Pharmacoepidemiology and Drug Safety, August 2013
  6. Drug Use Pattern of Rivaroxaban in the UK
    Carlos Martinez, Stephan Rietbrock, Kiliana Suzart-Woischnik, Mari-Ann Wallander.
    Pharmacoepidemiology and Drug Safety, August 2013
  7. Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis
    Marloes T Bazelier, Frank de Vries, Peter Vestergaard, Ron MC Herings, Arlene M Gallagher, Hubert GM Leufkens, Tjeerd-Pieter van Staa.
    Pharmacoepidemiology and Drug Safety, August 2013
  8. Test Data in General Practice Are Not Missing at Random – Can We Identify When They Are?
    Cormac J Sammon, Alison L Nightingale, Anne Miller, Kamal R Mahtani, Tim A Holt, Neil McHugh, Raashid A Luqmani, Corinne S de Vries.
    Pharmacoepidemiology and Drug Safety, August 2013
  9. Trends in Incidence Rates (IR) of Hip/Femur Fractures in 5 European Countries: A Comparison Using Electronic Health Care Records (e-HCR)
    Gema Requena, Victoria Abbing-Karahagopian, Consuelo Huerta, Marieke L De Bruin, Yolanda Alvarez, Montserrat Miret, Ulrik Hesse, Helga Gardarsdottir, Patrick Souverein, Jim Slattery, Cornelia Schneider, Marietta Rottenkolber, Sven Schmiedl, Miguel Gil, Mark CH De Groot, Andrew Bate, Ana Ruigó mez, Luis A Garcí a, Saga Johanson, Frank De Vries, Dolores Montero, Raymond Schlienger, Robert Reynolds, Olaf H Klungel, Francisco J De Abajo.
    Pharmacoepidemiology and Drug Safety, August 2013
  10. Harmonization of Outcome Extraction for Heart Failure across Data Sources in the SAFEGUARD Project
    Lorenza Scotti, Andrea Arfè Antonella Zambon, Silvana Romio, Niklas Schmedt, Giorgia De Berardis, Cormac Sammon, Miguel Gil, Elisa Martin, Gema Requena, Corine de Vries, John D Seeger, Giampiero Mazzaglia, Irene Bezemer, Cristina Varas-Lorenzo, Mark Smits, Peter Rijnbeek, Miriam Sturkenboom, Giovanni Corrao.
    Pharmacoepidemiology and Drug Safety, August 2013
  11. Incidence of Colorectal Cancer in Association with Diagnosed Hypertension
    Estel Plana, Ying Zhu, Christoph R Meier, Raymond G Schlienger.
    Pharmacoepidemiology and Drug Safety, August 2013
  12. Harmonization of Outcome Extraction for Ischemic and Hemorrhagic Stroke across Data Sources in the SAFEGUARD Project
    Niklas Schmedt, Miguel Gil, Elisa Martin, Gema Requena, Irene Bezemer, Giorgia De Berardis, Corine de Vries, Ingrid Leal, Gwen Masclee, Giampiero Mazzaglia, Peter Rijnbeek, Silvana Romio, Cormac Sammon, Lorenza Scotti, John Seeger, Mark Smits, Tania Schink, Christina Varas-Lorenzo, Miriam Sturkenboom, Edeltraut Garbe.
    Pharmacoepidemiology and Drug Safety, August 2013
  13. Factors Associated with Utilization of Saxagliptin in the US and UK
    Melissa S Nezamzadeh, Kevin Haynes, Dena M Carbonari, Craig Newcomb, Jason Roy, Serena Cardillo, Kimberly BF Leidl, Jennifer Wood Ives, Stephanie DeVore, Laura Horne, Betina Blak, Daina Esposito, Crystal Holick, Tjeerd Van Staa, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re III, Eileen E Ming, Sean Hennessy, Peter P Reese, K Rajender Reddy, David Margolis, Andrea Apter, Stephen E Kimmel, Cristin P Freeman, Hanieh Razzaghi.
    Pharmacoepidemiology and Drug Safety, August 2013
  14. Use of Glucagon-Like Peptide 1 Analogues and the Risk of Fracture in Type 2 Diabetes Patients
    Johanna HM Driessen, Hein A van Onzenoort, Arief Lalmohamed, Corinne Klop, Marloes Bazelier, Kees Neef, Frank de Vries
    Pharmacoepidemiology and Drug Safety, August 2013
  15. Parkinson's Disease and Risk of Retinal Degeneration
    Joan Fortuny, Estel Plana.
    Pharmacoepidemiology and Drug Safety, August 2013
  16. Transparency in Data Preparation for Drug Exposure Using the Clinical Practice Research Datalink and Sensitivity of Results to Various Assumptions
    Mohammad Movahedi, Mark Lunt, Therese Sheppard, Robyn Tamblyn, Nadyne Girard, Will Dixon.
    Pharmacoepidemiology and Drug Safety, August 2013
  17. Improving Consistency in Findings from Pharmacoepidemiological Studies: The IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Project
    Mark CH de Groot, Raymond Schlienger, Robert Reynolds, Helga Gardarsdottir, Juhaeri Juhaeri, Ulrik Hesse, Christiane Gasse, Marietta Rottenkolber, Markus Schuerch, Xavier Kurz, Olaf H Klungel.
    Pharmacoepidemiology and Drug Safety, August 2013
  18. Male Breast Cancer in Users of Finasteride and Dutasteride: A Case-Control Study
    Ruben G Duijnhoven, Sabine MJM Straus, Patrick C Souverein, Anthonius de Boer, Arno W Hoes, Marie L De Bruin.
    Pharmacoepidemiology and Drug Safety, August 2013
  19. Balancing Individual Benefits and Risks of Warfarin in Patients with Atrial Fibrillation
    Rianne van den Ham, Olaf H Klungel, Hubert GM Leufkens, Tjeerd P van Staa.
    Pharmacoepidemiology and Drug Safety, August 2013
  20. Total Mortality Rates across Multiple Databases: Benchmarking Results from a Distributed Data Network - The SAFEGUARD Project
    John D Seeger, Silvana Romio, Cristina Varas-Lorenzo, Lorenza Scotti, Andrea Arfè Antonella Zambon, Miguel Gil, Gema Requena, Irene Bezemer, Georgia De Berardis, Corinne DeVries, Ingrid Leal, Gwen Masclee, Gianluca Trifiró Peter Rijnbeek, Cormac Sammon, Niklas Schmedt, Mark Smits, Giovanni Corrao, Miriam Sturkenboom.
    Pharmacoepidemiology and Drug Safety, August 2013

  1. Comparison of Seven Electronic Healthcare Databases in EU Countries Using a Standardized Methodology; a Descriptive Study on the Exposure to Calcium-Channel Blockers (CCBs)
    Mark CH de Groot, Rianne Van den Ham, Marieke De Bruin, Consuelo Huerta Alvarez, Miguel Gill, Ana Afonso, Gema Requena, Ulrik Hesse, Pernille Falberg Rø nn, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Sven Schmiedl, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Lamiae Grimaldi-Bensouda
    Pharmacoepidemiology and Drug Safety, August 2013
  2. Antiepileptic Drug Use in Seven Electronic Health Record Databases in Europe: A Methodological Comparison
    Mark CH De Groot, Markus Schuerch, Frank De Vries, Ulrik Hesse, Belé n Oliva, Consuelo Huerta Alvarez, Miguel Gil, Gema Requena, Francisco Abajo, Ana Afonso, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Sven Schmiedl, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf Klungel.
    Pharmacoepidemiology and Drug Safety, August 2013
  3. Comparison of Six Electronic Healthcare Databases in Europe Using Standardized Protocols: A Descriptive Study on the Incidence of Cancer
    Ana S Afonso, Mark CH De Groot, Rianne Van den Ham, Marie L Bruin, Consuelo Huerta Alvarez, Miguel Gil, Ulrik Hesse, Pernille F Rø nn, Patrick C Souverein, Yolanda Alvarez, Jim Slattery, Marietta Rottenkolber, Liset Van Dijk, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Lamiae Grimaldi-Bensouda.
    Pharmacoepidemiology and Drug Safety, August 2013
  4. Antidepressant Prescribing in Five European Countries: Application of Common Methods To Assess the Variation in Prevalence
    V Abbing-Karahagopian, C Huerta, PC Souverein, F de Abajo, HGM Leufkens, J Slattery, Y Alvarez, M Montserrat, M Gil, U Hesse, G Requena, F de Vries, M Rottenkolber, S Schmiedl, R Reynolds, R Schlinger, M de Groot, OH Klungel, TP van Staa, L van Dijk, ACG Egberts, H Gardarsdottir, ML De Bruin.
    Pharmacoepidemiology and Drug Safety, August 2013
  5. A Cohort Analysis To Measure the Effect of Orlistat or Bariatric Surgery on Weight and Body Mass Index in a General UK Population Sample
    Ian J Douglas, Krishnan Bhaskaran, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, August 2013
  6. Harmonization of Acute Myocardial Infarction Identification from Different Databases in the SAFEGUARD Project
    Gwen MC Masclee, Miriam CJM Sturkenboom, Ingrid A Leal, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martí n, Gema Requena, Cormac Sammon, Niklas Schmedt, John Seeger, Lorenza Scotti, Gianluca Trifiro, Cristina Varas-Lorenzo, Corinne de Vries, Mark Smits, Peter Rijnbeek, Silvana Romio.
    Pharmacoepidemiology and Drug Safety, August 2013
  7. Harmonization of Diagnoses for Acute Pancreatitis Identification from Different Databases in the SAFEGUARD Project
    Gwen MC Masclee, Silvana Romio, Ingrid A Leal, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martí n, Gema Requena, Cormac Sammon, Niklas Schmedt, John Seeger, Lorenza Scotti, Gianluca Trifiro, Cristina Varas-Lorenzo, Corinne de Vries, Mark Smits, Peter Rijnbeek, Miriam CJM Sturkenboom.
    Pharmacoepidemiology and Drug Safety, August 2013
  8. Benefits of Different Propensity Score Methods for Evaluation of Associations and Channeling Bias over Time: Pneumonia and Inhaled Corticosteroid in a COPD New User Cohort
    Hoa V Le, Rachael L DiSantostefano, Tim Sampson, Chi T Truong, Kourtney J Davis.
    Pharmacoepidemiology and Drug Safety, August 2013
  9. Comparison of Covariate Selection Approaches for Propensity Score (PS) Derivation for Multiple Health Outcomes of Interest (HOIs): An Empirical Example
    BAnn Marie McNeill, Cynthia J Girman, Zhiwen Liu, Robert J LoCasale, Richard Wyss, Ying Su, Til Sturmer.
    Pharmacoepidemiology and Drug Safety, August 2013
  10. Identifying Patients in Electronic Healthcare Data When No Diagnostic Codes Are Available for the Disease of Interest: Critical Limb Ischemia Example
    Jennifer Campbell, George Geroulakos, Tjeerd van Staa.
    Pharmacoepidemiology and Drug Safety, August 2013
  11. Lessons Learned from Implementation of a Prospective, Observational Cohort Study To Assess Risk of Spontaneous Abortion (SA) Following Administration of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine around Conception
    Christina Chambers, Diana Johnson, Ronghui Xu, Dominique Rosillon, Judith van den Bosch, Laurence Baril, Sylvia Taylor.
    Pharmacoepidemiology and Drug Safety, August 2013
  12. Factors and Characteristics for Medication Initiation in Type 2 Diabetes Patients in the UK
    Alison K Wright, Martin K Rutter, Richard Emsley, Darren M Ashcroft, Douglas Steinke.
    Pharmacoepidemiology and Drug Safety, August 2013
  13. An Epidemiological Study Examining the Risk of Malignancy in Patients with Inflammatory Bowel Disease
    Jessica C Wilson, Raoul I Furlano, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, August 2013
  14. Effervescent, Dispersible and Soluble Medications Increase Cardiovascular Events
    Jacob George, Waseem Majeed, Thomas M MacDonald, Isla S Mackenzie, Li Wei.
    Pharmacoepidemiology and Drug Safety, August 2013
  15. Baseline Characteristics and Comorbidities among United Kingdom Males Prior to Testosterone Treatment Compared to Non-Users Stratified by Body Mass Index (BMI)
    Hu Li, Jonathan Swain, Karin Benoit, Nancy Ostrowski, Stephen Motsko.
    Pharmacoepidemiology and Drug Safety, August 2013
  16. Case-Control Analysis on Metformin and Cancer of the Esophagus
    Claudia Becker, Christoph R Meier, Susan S Jick, Michael Bodmer.
    Pharmacoepidemiology and Drug Safety, August 2013
  17. Calcium Channel Blockers and Esophageal Cancer: A Case-Control Analysis
    Claudia Becker, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, August 2013
  18. Oral Glucocorticoids and the Risk of Incident Type II Diabetes Mellitus in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
    Mohammad Movahedi, Mark Lunt, David Ray, Will Dixon.
    Pharmacoepidemiology and Drug Safety, August 2013
  19. Physicians' prescribing preferences are a potential instrument for patients' actual prescriptions of antidepressants.
    Davies, Neil; Gunnell, David; Thomas, Kyla; et al.
    American Journal of Epidemiology. 2013;177:S108.
  20. Determinants of Prescribing Inhaled Long-Acting Beta-Agonist Bronchodilators As Monotherapy to Adults with Asthma.
    Ali, Ayad K.
    Journal of Allergy and Clinical Immunology. 2013;131(2):AB4.
  21. Weight loss of ≥3% in type II diabetes patients is associated with weight change property of newly prescribed anti-diabetic medicine in anti-depressant users over a 12-month follow-up period.
    Ching-Ching Lin, Jayanti Mukherjee, Hugh Kawabata, Susan Colilla, Gail Wygant.
    ISPOR 16th Annual European Congress, 2013.

Abstract & Posters - 2012

  1. Combining Data in Multi-Country Studies: Mega-Analysis vs. Meta-Analysis
    Marloes T Bazelier, Joan Bentzen, Peter Vestergaard, Hubert GM Leufkens, Frank de Vries.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S11
  2. Pattern of Anticoagulation Control and Risk of Stroke, Bleeding and Mortality
    Hendrika A van den Ham, Olaf H Klungel, Hubert GM Leufkens, Tjeerd P van Staa.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S22
  3. The Use of Single, Dual, or Triple Antithrombotic Therapy and the Risk of Bleeding Events in Patients with Atrial Fibrillation
    Laurent Azoulay, Sophie Dell’Aniello, Teresa Simon, Christel Renoux, Samy Suissa.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S22
  4. Heralding of STEMI and NSTEMI: A Prospective CALIBER Study
    Emily Herrett, Julie George, Harry Hemingway, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S24
  5. Characteristics of Patients Initiating Oral Antidiabetic Therapy in the UK: Evidence of Delayed Treatment?
    Andrew Maguire, Beth Mitchell.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S27
  6. Databases, Biologics, and Biomarkers: The Challenges and Rewards of Incorporating Biological Specimens in Pharmacoepidemiologic Research
    Leah B Sansbury, Kimberly A Wilson, Joanna F Haas, Bruce Carleton, Tjeerd-Pieter van Staa, Catherine Schafer.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S38
  7. Use of Antimalarial Chemoprophylaxis and the Risk of Developing Eye Disorders
    Cornelia Schneider, Miriam Adamkova, Susan S Jick, Patricia Schlagenhauf, Katie Miller, Hans-Georg Rhein, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S93
  8. Trends in Paediatric ADHD Drug Prescription in the UK and Cardiovascular Event Rates
    Raphaelle Beau Lejdstrom, Stephen JW Evans, Ian Douglas, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S136
  9. Risk of Acute Renal Failure Likely Due to Concurrent Use of ACE-Inhibitors, Angiotensin Receptors Blockers, Diuretics and Anti-Inflammatory Drugs
    Francesco Lapi, Laurent Azoulay, Hui Yin, Samy Suissa
    Pharmacoepidemiology and Drug Safety, 2012; 21: S163
  10. Proton Pump Inhibitors and Traditional Nonsteroidal Anti-Inflammatory Drugs and the Risk of Acute Interstitial Nephritis and Acute Kidney Injury
    Charles E Leonard, Cristin P Freeman, Craig W Newcomb, Peter P Reese, Maximilian Herlim, Warren B Bilker, Sean Hennessy, Brian L Strom.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S179
  11. Nonsteroidal Anti-Inflammatory Drug Use and Brain Tumour Risk: A Nested Case-Control Study in the General Practice Research Database
    Michael A O’Rorke, Finian J Bannon, Liam J Murray, Carmel M Hughes, Marie M Cantwell, Anna T Gavin, Chris R Cardwell.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S180
  12. Orlistat and the Risk of Acute liver Injury: A Self- Controlled Case-Series Study in United Kingdom General Practice Research Database
    Julia Langham, Liam Smeeth, Ruth Brauer, Krishnan Bhaskaran, Ian Douglas.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S190
  13. Risk of Incident Cardiovascular Disease Events in Patients with Psoriasis: A Retrospective Cohort Study Using the General Practice Research Database
    Paola Primatesta, Estel Plana, Zuleika Aponte Torres.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S192
  14. Change in Exposure in Studies of Chronic Conditions: Insights from a Mixed Effects Multinomial Logit Model
    Maurille Feudjo Tepie, Andrew Roddam, Cathy Critchlow, Andrew Taylor, Samara Ferguson, Shelley Fordred, Jonathan Bayly.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S252
  15. Risk of Acute Myocardial Infarction (AMI), Stroke, or Death in GPRD Patients Treated with Olmesartan (Olm) or Other Angiotensin Receptor Blockers (ARBs)
    Esther H Zhou, Kate Gelperin, David J Graham, Mark Levenson, Martin Rose, Ya-Hui Hsueh, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S254
  16. Diuretics and the Risk of Developing Gout
    Saskia G Bruderer, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S256
  17. Spironolactone and the Risk of Breast Cancer: A Cohort Study
    Isla S Mackenzie, Thomas M MacDonald, Alastair M Thompson, Steven Morant, Li Wei.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S258
  18. Cardiovascular Diseases and Drugs and the Risk of Developing Rosacea
    Julia Spoendlin, Johannes J Voegel, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S259
  19. The Use of Pioglitazone and the Risk of Bladder Cancer in Patients with Type 2 Diabetes
    Laurent Azoulay, Hui Yin, Kristian B Filion, Jonathan Assayag, Agnieszka Majdan, Michael Pollak, Samy Suissa, Samy Suissa.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S271
  20. Type 2 Diabetes Mellitus and Cancer Risk: A Population-Based Study
    Jinghua He, Tzuyung D Kou, Kimberly G Brodovicz, Samuel S Engel, Amy Sun, Cynthia J Girman.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S273

  1. Estimating Chronic Kidney Disease in a UK population with Type II Diabetes Mellitus
    Claudia S Cabrera, Alex Asiimwe, Alison Lee.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S273
  2. Algorithm To Estimate Duration of Known Type 2 Diabetes in Electronic Healthcare Databases
    Kimberly G Brodovicz, T Doug Kou, Rishi Desai, Se Li, Samuel S Engel, Charles M Alexander, Cynthia J Girman.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S274
  3. Using Functional Principal Component Analysis (FPCA) for Sparse Longitudinal Data (SLD): Example of HbA1c in Patients with Diabetes Mellitus
    Therese M Sheppard, William G Dixon.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S274
  4. Diabetes Mellitus, Antidiabetic Drugs and the Risk of Developing Rosacea
    Julia Spoendlin, Johannes J Voegel, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S275
  5. Metformin Does Not Alter the Risk of Lung Cancer: A Case–Control Analysis
    Michael Bodmer, Claudia Becker, Christian Meier, Susan SJick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S278
  6. Utilisation and Characteristics of New Users of Oral Antidiabetes Drugs (OAD) in the UK: 2006 2010
    Andrew Maguire, Beth Mitchell.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S285
  7. The Prescribing of Fibrates in General Practice in the UK and the Impact of Regulatory Advice
    Katherine L Donegan.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S289
  8. Use of Bayesian Method To Predict Missing Lifestyle Information in the General Practice Research Database (GPRD)
    Jamie T Laudati, Tzuyung D Kou, Kimberly G Brodovicz, Cynthia J Girman, Hanzhe Zheng.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S303
  9. A Clinical Classification Dictionary for Read Codes in the General Practice Research Database
    Hoa V Le, Chi T Truong, David Webb, Lakshmi Mynepalli, Elizabeth Hodgson, Dimitri Bennett, John Logie, Carlyne Averell.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S304
  10. Developing Quality Scores for Electronic Health Records for Clinical Research
    A Rosemary Tate, Natalia Beloff, Timothy Williams, Shivani Puri, Tjeerd van Staa.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S305
  11. Anti-Dementia Drugs in Patients with Alzheimer’s Disease and the Risk of Developing Seizures or Epilepsy: A Population-Based Nested Case–Control Analysis
    Patrick Imfeld, Michael Bodmer, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S332
  12. The Role of Surveillance Bias in the Incidence of the Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders
    Amanda B Wilson, Marianne N Prout, Tuhina Neogi, Susan Jick.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S336
  13. Validation of Congenital Cardiac Malformations in the General Practice Research Database
    Fatmatta Kuyateh, Andrea V Margulis, Yulan Ding, Adel Abou-Ali, Marian Callaham, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S336
  14. The Real Potential of Routine Electronic Health Records for Clinical Trials: Putting Them to the Test
    Tjeerd P van Staa, Liam Smeeth, John Parkinson, Kourtney Davis, Hubert GM Leufkens.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S340
  15. Use of Orlistat and Risk of Colorectal Cancer
    Jin-Liern Hong, Robert Sandler, Christoph Meier, Susan Jick, Til Sturmer.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S345
  16. Bisphosphonates and Esophageal Cancer in the GPRD
    Alec Walker, Julie Chandler, Robert Lubwama, Nancy Santanello.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S345
  17. Androgen Deprivation Therapy and the Risk of Colorectal Cancer in Prostate Cancer Patients
    Jonathan Assayag, Hui Yin, Samy Suissa, Laurent Azoulay.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S346
  18. Patterns of Antidepressant and Antipsychotic Use during Pregnancy
    Andrea V Margulis, Elizabeth M Kang, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S371
  19. Asthma Management in Pregnancy
    Rachel Charlton, Annie Hutchison, Kourtney Davis, Corinne de Vries.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S381
  20. Major Malformations in Babies Whose Mothers Had Pre-Existing Diabetes during Pregnancy
    Anita McGrogan, Julia Snowball, Corinne S de Vries.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S388

  1. Validation of Cataract Diagnosis in the UK General Practice Research Database
    Elizabeth M Kang, Adel Abou-Ali, Simone P Pinheiro, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S394
  2. Validation of Glaucoma Diagnosis in the UK General Practice Research Database
    Adel Abou-Ali, Elizabeth M Kang, Simone P Pinheiro, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S394
  3. An Algorithm Using Free-Text To Identify Sudden Cardiac Death in the General Practice Research Database
    Meghan Jones, Elizabeth Brunner, Elena Moscarelli, Chetan Shatapathy, Justo Sierra-Johnson, Tjeerd P van Staa, Stephen Motsko.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S399
  4. Prescribing of Strong Opioid Analgesics by UK Primary Care Physicians from 2000 to 2010
    Che Suraya Zin, Li-Chia Chen, Roger D Knaggs.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S403
  5. Exposure to Non Steroidal Anti-Inflammatory Drugs and Risk of Cervical Intraepithelial Neoplasia Grade III
    Janine A Glover, Jessica C Wilson, Liam J Murray, Lesley A Anderson, Christopher R Cardwell, Marie M Cantwell, Carmel M Hughes.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S408
  6. Etoricoxib in the UK: Continuing vs. New Users after the COX-2 Urgent Safety Restriction (USR)
    Douglas J Watson, Vinay Mehta.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S415
  7. Etoricoxib Prescribing by GPs in the UK after the COX- 2 Urgent Safety Restriction (USR)
    Douglas J Watson, Vinay Mehta.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S415
  8. Incidence of Cardiovascular (CV) Events with Etoricoxib in the UK after the COX-2 Urgent Safety Restriction (USR)
    Douglas J Watson, Vinay Mehta.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S415
  9. Impact of Gastroesophageal Reflux Disease (GERD) Definition on Incidence Rate of Endoscopies among Osteoporotic Patients
    Robert N Lubwama, Julie Chandler, Tzuyung D Kou.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S421
  10. Utilization Patterns of Strattera in Germany, Netherlands, Sweden and UK
    Kwame Appenteng, Angelo Camporeale, Michel Denarie, Jennifer Millard, Stephen Motsko.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S427
  11. Prescribing Trends of Dosulepin in General Practice: Reducing the Potential for Fatal Overdose
    Jenny Wong, Suzie Seabroke
    Pharmacoepidemiology and Drug Safety, 2012; 21: S433
  12. A Comparison between the Standard Self Controlled Case Series Design and a Modification To Account for Events That Censor the Observation Period
    Ruth Brauer, Liam Smeeth, Karim Anaya-Izquierdo, C Paddy Farrington, Heather Whitaker, Ian Douglas.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S439
  13. A Cohort Analysis of the Association between Parkinson’s Disease and Cancer Using the UK General Practice Research Database
    Kevin Wing, Ian Douglas, Krishnan Bhaskaran, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S442
  14. Relative Risk of Myeloid Neoplasms in Patients Taking Benzodiazepines
    Amanda B Wilson, Marianne N Prout, Tuhina Neogi, Susan Jick.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S447
  15. Risk of Mortality (Including Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database
    Tarita Murray-Thomas, Deven Patel, Meghan Jones, Elizabeth Brunner, Chetan Shatapathy, Stephen Motsko, Tjeerd P van Staa.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S449
  16. Risk of Cardiac Mortality (Including Sudden Cardiac Death) in Olanzapine Users: A Study with the General Practice Research Database
    Meghan Jones, Deven Patel, Elizabeth Brunner, Chetan Shatapathy, Stephen Motsko, Giedra Campbell, Tarita Murray-Thomas, Tjeerd P van Staa.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S449
  17. Risk of Developing Alzheimer’s Disease in Association with Influenza Infections
    Patrick Imfeld, Stephen Toovey, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S455
  18. Relative Risk of Myeloid Neoplasms in Patients with Autoimmune Disease
    Amanda B Wilson, Marianne N Prout, Tuhina Neogi, Susan Jick.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S467
  19. The Risk of Developing Depression in Association with Previously Diagnosed Influenza Infection
    Delia Bornand, Stephen Toovey, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S476
  20. 5-alpha Reductase Inhibitors and Prostate Cancer Incidence and Mortality among Men with Benign Prostatic Hyperplasia
    Krishnan Bhaskaran, Ian Douglas, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S479
  21. Hormone Replacement Therapy and the Risk of Developing Gout
    Saskia G Bruderer, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2012; 21: S479

Abstract & Posters - 2011

  1. Statin Prescribing Following an Acute Coronary Syndrome: Are the NICE Guidelines Being Followed?
    Boggon R, Eaton S, Timmis A, Hemingway H, Gabriel Z, Minhas I, van Staa T
    Pharmacoepidemiology and Drug Safety, 2011; 20: S20
  2. Use of Thiazolidinediones and Risk of Osteoporotic Fracture: Disease or Drugs?
    Bazelier M, Gallagher A, van Staa T, Cooper C, Leufkens H, Vestergaard P, Frank De Vries.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S26
  3. Creating a Mother Baby Link and Pregnancy Register for a UK Population
    Boggon R, Gallagher A, Williams T, van Staa T
    Pharmacoepidemiology and Drug Safety, 2011; 20: S44
  4. Use of Thiazolidinediones and Risk of Osteoporotic Fracture: The Danish National Databases
    Bazelier M, Gallagher A, van Staa T, Cooper C, Leufkens H, Vestergaard P
    Pharmacoepidemiology and Drug Safety, 2011; 20: S119
  5. Risk of Fracture in Patients with Myasthenia Gravis
    Bazelier M, Pouwels S, Javaid K, Cooper C, Hilton-Jones D, Verschuuren J, van Staa T, De Vries F.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S119
  6. Cancer Recording and Mortality in the General Practice Research Database and Linked Cancer Registry, Hospital and Death Certificate Data
    Boggon R, Moller H, Gallagher A, Leufkens H, Hammad T, Zhang H, van Staa T
    Pharmacoepidemiology and Drug Safety, 2011; 20: S162
  7. STAtin-Induced Muscle Toxicity: Exploration Using the UK General Practice Research Database -Recruitment
    Campbell J, van Staa TP, McCann G, O’Meara H, Pirmohamed M.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S183
  8. Linkage of the General Practice Research Database (GPRD) with Other Data Sources
    Gallagher AM, Puri S, van Staa TP.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S230
  9. The Risk of Cancer Associated with Angiotensin-II Receptor Blockers
    Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S279
  10. Assessment of Long-Term Adverse Drug Reactions, Regulatory Needs and Methodological Challenges
    Duijnhoven RG, Straus SMJM, van Staa TP, Moride Y, Grimaldi LM, De Bruin ML
    Pharmacoepidemiology and Drug Safety, 2011; 20: 268
  11. Impact of treatment persistence and compliance on health care resource utilisation and total health care cost in post menopausal women prescribed oral bisphosphonates – a retrospective study using the general practice research database (GPRD)
    Murray-Thomas T, Patel D, Williams T, van Staa T
    Value in Health, Volume 14 Number May 2011: A126
  12. Clopidodgrel and statin prescribing patterns in acs patients – an observational study using linked secondary and primary care data in a uk population 2003-2009
    Boggon R, Fox KA, Begg A, Ray K, Timmis A, Hemingway H, Emmas CE, Van staa T
    Value in Health, Volume 14 Number Nov 2011: A368
  13. Resource use in patients with acute coronary syndrome – an observational study across secondary and primary care in a UK population
    Boggon R, Fox KA, Begg A, Ray K, Timmis A, Hemingway H, Emmas CE,Van staa T
    Value in Health, Volume 14 Number Nov 2011: A382
  14. Association between Minocycline and Thyroid Cancer in the GPRD: Preliminary Findings
    Sigal Kaplan, Marian Callaham, Yulan Ding, Stephine Kee- ton, Mark Levenson, Naomi Lowy, Tarek Hammad.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S36
  15. SSRIs Use during Pregnancy and the Risk of Cardiac Congenital Malformations using the General Practice Research Database
    Adel Abou-Ali, Marian Callaham, Fatmatta Kuyateh, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S43
  16. Advancing the Field of Drug Safety in Pregnancy: A Decade of Abstracts Presented at ICPE
    Deborah Covington, Kyna Gooden, Laura McKain.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S46
  17. Swine Flu Vaccination in Pregnancy and Associated Miscarriage Risk
    Cormac J Sammon, Anita McGrogan, Julia Snowball, Cor- inne S de Vries.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S58
  18. Epidemiology of Pneumoconioses in the U.K. General Population
    Rajeev K Amar, Susan S Jick, Daniel Rosenberg, Toby M Maher, Christoph R Meier
    Pharmacoepidemiology and Drug Safety, 2011; 20: S61
  19. Medications in Pregnancy Special Interest Group: Improving the Quality of Science and Expanding Knowledge
    Deborah Covington, Kyna Gooden, Laura McKain.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S73
  20. Drug-/Radiation-Induced Interstitial Lung Disease in the UK General Population: Incidence, Drug Use and Characteristics at Diagnosis
    Rajeev K Amar, Susan S Jick, Daniel Rosenberg, Toby M Maher, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S84

  1. An Analysis of HRT Usage between 2000 and 2009 Using GPRD in the UK
    Jakob Petersen, Jane Woolley, Dervla Mahoney.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S101
  2. A Cohort Study Using GPRD and MINAP Data To Investigate the Possible Drug Interaction between Clopi- dogrel and Cytochrome P450 2C19 Inhibitors
    Ian Douglas, Liam Smeeth, Aroon Hingorani, Anthony Grosso, Stephen Evans.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S123
  3. Thiazolidinidiones and the Risk of Myocardial Infarction
    Rohini K Hernandez, Timothy L Lash, Cathy W Critchlow, Susan S Jick.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S123
  4. Antipsychotic Drugs and Risk of Idiopathic Venous Thromboembolism: A Nested Case Control Study Using the GPRD
    Chieko Ishiguro, Lin Li, Susan S Jick.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S130
  5. Androgen Deprivation Therapy and the Risk of Stroke and Transient Ischemic Attacks in Patients with Prostate Cancer
    Laurent Azoulay, Hui Yin, Serge Benayoun, Jean-Francois Boivin, Samy Suissa.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S130
  6. Effect of Simultaneous Use of Oestrogens and Statins on the Risk for Venous Thromboembolism in Post- Menopausal Women
    Ruben Duijnhoven, Sophie dell’Aniello, Christel Renoux, Vicky Tagalakis, Mirjam Knol, Olaf Klungel, Samy Suissa.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S131
  7. Differences in Oral Candidiasis Risk between Different Inhaled Corticosteroids
    Alison L Nightingale, Annie Hutchison, Corinne S de Vries.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S141
  8. Comparison of Retention Rates of First Line Anti-epileptic Drugs in Children in the UK
    Raphaelle Beau, Ian Douglas, Evans Stephen, Tim Clayton, Liam Smeeth
    Pharmacoepidemiology and Drug Safety, 2011; 20: S152
  9. Comparison of Methods To Define Lifestyle Risk Factors in the General Practice Research Database (GPRD)
    Jamie T Laudati, Tzuyung D Kou, Kimberly A Wilson, Kimberly G Brodovicz, Cindy J Girman.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S169
  10. Cancer Identification in the General Practice Research Data Base
    A M Walker, J M Chandler, R Lubwama, N C Santanello.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S175
  11. Impact of the Quality Outcomes Framework on Hypertension Coding in GPRD
    Lesley H Wise,1 David Irvine,1 Motonobu Sakaguchi,2 Gregory Fusco.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S176
  12. Association between Antidepressant Drugs and Cancer in the UK-Based General Practice Research Database: A Cohort Study
    Adel Abou-Ali, Elizabeth M Kang, Simone Pinheiro, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S192
  13. Using the Self Controlled Case Series Method To Assess the Risk of Myocardial Infarction in GPRD- Registered Users of Antipsychotic Agents
    Ruth Brauer, Ian Douglas, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S193
  14. Migraine in Patients with Rosacea
    Julia Spoendlin, Cornelia Schneider, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S199
  15. Agreement between COPD-Related Hospitaliza- tions Identified Using Two Sources: General Practice Research Database (GPRD) and Linked Hospitalization Episode Statistics (HES) Data
    Rachael L DiSantostefano, Richard Baxter, Hana Mu llerova.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S230
  16. Impact of Look-Back Period on Baseline Patient Characteristics and Subsequent Risk Estimates in the General Practice Research Database (GPRD)
    Tzuyung D Kou, Kimberly G Brodovicz, Cindy J Girman
    Pharmacoepidemiology and Drug Safety, 2011; 20: S254
  17. Safety of Adjuvanted Pandemic Influenza Vac- cines: Background Rate of Narcolepsy in Europe
    J Dieleman, C Lecomte, M Schuemie, Avan Rolleghem, A Hviid, H Svanstrom, D Mølgaard-Nielsen, J Jokinen, H Nohynek, T Kilpi, J Storsaeter, N van der Maas, H Heijbel, L Arnheim-Dahlstrøm, P Sparen, C Sammon, C de Vries, G Plazzi, A Menna, F Trotta, C Santuccio, K Johansen, P Kramarz, D Weibel, J Bonhoeffer, M Sturkenboom.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S260
  18. Assessing Treatment Patterns: Novel Methods and Applications
    Sonia S Maruti, E Dawn Flick, Marloes Bazelier, Frank De Vries, Krista F Huybrechts, Drew Levy, Andrew Roddam, Wei Dong.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S267
  19. Use of Metformin or Other Antidiabetic Drugs and Pancreatic Cancer: A Case-Control Analysis
    Michael Bodmer, Claudia Becker, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S270
  20. Macrogol Laxatives and Colorectal Cancer Risk
    Rachel A Charlton, Julia M Snowball, Katherine Bloomfield, Corinne S de Vries.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S270

  1. The Risk of Myocardial Infarction and Opioids Use for Non-Cancer Pain: A Nested Case-Control Study in UK General Practice Research Database (GPRD)
    Lin Li, Soko Setoguchi, Susan S Jick.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S271
  2. Synergistic Effect of Type 2 Diabetes (T2D) and History of Pancreatitis on Pancreatic Cancer Risk: A Retrospective Cohort Study from the General Practice Research Database (GPRD)
    Kimberly G Brodovicz, Tzuyung D Kou, Charles M Alexander, Samuel Engel, Cynthia J Girman.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S283
  3. Risk Factors Associated with the Incidence of Vaginitis and Balinitis among Patients with Type 2 Diabetes in a Community Practice Setting in the UK
    Andres Gomez-Caminero, Ishan Hirji, Susan Andersson, Niklas Hammar.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S287
  4. Risk Factors Associated with the Incidence of Urinary Tract Infections among Patients with Type 2 Diabetes in a Community Practice Setting in the UK
    Andres Gomez-Caminero, Ishan Hirji, Susan Andersson, Niklas Hammar.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S287
  5. Thiazolidinidiones and the Risk of Microvascular Disease
    Rohini K Hernandez, Timothy L Lash, Cathy W Critchlow, Susan S Jick.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S289
  6. Metformin or Other Antidiabetic Drugs and the Risk of Developing Alzheimer’s Disease: A Population- Based Case-Control Study
    Patrick Imfeld, Yolanda B Brauchli, Cornelia Schneider, Michael Bodmer, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S289
  7. Diabetes and the Risk of COPD
    Cornelia Schneider, Susan S Jick, Ulrich Bothner, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S292
  8. Association between Antidepressant Drugs and Cataracts in the UK-Based General Practice Research Database: A Cohort Study
    Adel Abou-Ali, Elizabeth M Kang, Simone Pinheiro, Tarek A Hammad.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S294
  9. Alzheimer’s Disease and the Risk of Subsequent Stroke or Transient Ischaemic Attack: A Population- Based Nested Case-Control Analysis
    Patrick Imfeld, Yolanda B Brauchli, Markus Schuerch, Noah J Robinson, Susan S Jick, Christoph R Meier.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S298
  10. Patient’s Right to Self-Determination and Its Impact on All Cause Morality Risk Estimates in Dementia Patients - A Observational Study Using General Practice Research Database (GPRD)
    Tzuyung D Kou, Edward A Bortnichak.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S299
  11. A Self-Controlled Case-Series Study To Assess the Effect of Orlistat on the Risk of Idiopathic Acute Liver Injury, Using Data from the United Kingdom General Practice Research Database
    Julia Langham, Ian Douglas, Ruth Brauer, Krishnan Bhas- karan, Liam Smeeth
    Pharmacoepidemiology and Drug Safety, 2011; 20: S306
  12. Different Approaches to Instrumental Variable Analysis of Antidiabetic Effect of Bezafibrate
    Bing Cai, Sean Hennessy, Dylan Small, James H Flory, Thomas R Ten Have.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S310
  13. How Long Do Children Stay on Antiepileptic Treatments in the UK?
    Raphaelle Beau, Ian Douglas, Stephen Evans, Tim Clayton, Liam Smeeth.
    Pharmacoepidemiology and Drug Safety, 2011; 20: S317
  14. Impact of the Quality Outcomes Framework on Chronic Kidney Disease Coding in GPRD
    Lesley H Wise, David Irvine, Motonobu Sakaguchi, Gregory Fusco
    Pharmacoepidemiology and Drug Safety, 2011; 20: S323
  15. Developing quality scores for electronic health records for clinical research: A study using the general practice research database.
    Tate AR, Williams T, Puri S, Beloff N, Van Staa T.
    International Conference on Information and Knowledge Management, 2011, Proceedings: 35-41.
  16. Automatically estimating the incidence of symptoms recorded in GP free text notes.
    Koeling R, Tate AR, Carroll JA.
    International Conference on Information and Knowledge Management, 2011, Proceedings: 43-49.

Abstract & Posters - 2010

  1. Hip/Knee Arthroplasty and Risk of Hip Fracture: A Population-Based Case-Control Study
    Lalmohamed A, Arden N, van Staa TP, Leufkens HGM, de Vries F.
    Pharmacoepidemiology and Drug Safety, 2010; 19: S27
  2. Recruitment Strategy for Genetic Data Collection: The UK General Practice Research Database
    Setakis E, de Vries F, Pirmohamed M, van Staa TP
    Pharmacoepidemiology and Drug Safety, 2010; 19: S37
  3. Linking UK Death Certificate Data to UK Primary Care Data (GPRD) To Obtain Cause of Death
    Setakis E, Gallagher A, Williams TW, van Staa TP
    Pharmacoepidemiology and Drug Safety, 2010; 19: S83
  4. Use of Antidepressant Drugs and Risk ofOsteoporotic and Non-Osteoporotic Fractures: Focus on the Affinity for the Serotonin Receptor
    Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HGM, de Vries F.
    Pharmacoepidemiology and Drug Safety, 2010; 19: S121
  5. Risk of Fracture in Patients with Multiple Sclerosis:The General Practice Research Database
    Bazelier M, van Staa TO, Leufkens H, Vestergaard P, de Vries F.
    Pharmacoepidemiology and Drug Safety, 2010; 19: S129
  6. Characterics of Exposure to Non-Steroid Anti-Inflammatory Drugs in European Databases
    de Vries F, Kieler H, van Dijk L, Svensson T, van Staa TP
    Pharmacoepidemiology and Drug Safety, 2010; 19: S174
  7. Linking Primary Care Data (UK GPRD) to Hospital Records (HES)
    Eaton S, Setakis E, Williams TW, van Staa TP
    Pharmacoepidemiology and Drug Safety, 2010; 19: S195
  8. Change in Drug Utilization Patterns in Statin Users with Increased Creatine Phosphokinase (CPK) Levels
    de Vries F, Setakis E, van Staa TP
    Pharmacoepidemiology and Drug Safety, 2010; 19: S206
  9. Risk of Cataract in Patients with Multiple Sclerosis: A Population-Based Cohort Study
    S Mu¨ ller-Schotte, M Bazelier, van Staa TP, Leufkens HGM, de Vries F
    Pharmacoepidemiology and Drug Safety, 2010; 19: S259
  10. Cause of Death in Patients with Multiple Sclerosis and Controls: The General Practice Research Database
    Lalmohamed A, Bazelier MT, van Staa TP
    Pharmacoepidemiology and Drug Safety, 2010; 19: S276
  11. Linking UK Death Certificate Data to UK Primary Care Data (General Practice Research Database)
    Setakis E., Puri S, Gallagher A, Eaton S, De Vries F, Williams TW, van Staa TP. GPRD,
    Pharmacoepidemiology and Drug Safety, 2010; 19: S310
  12. Representativeness of Subset of the General Practice Research Database (GPRD) Linked to Other Data Sources
    Setakis E., Puri S, Williams TW.
    Pharmacoepidemiology and Drug Safety, 2010; 19: S311

Abstract & Posters - 2009

  1. Prior Event Ratio Adjustment: A magic bullet or more of the same?
    Gallagher A, MSC, deVries Frank, PhD and vanStaa Tjeerd
    Pharmacepidemiology Drug Safety 2009:18;S1-S273.032
  2. Outcomes following a hip fracture and length of hospitalisation: the General Practice Database.
    Gallagher A, deVries Frank, Ariely Rinat, vanStaa Tjeerd.
  3. Long-Acting-beta2-agonists in Audit asthma and the pattern of risk of death and severe asthma outcomes: A study with the UK General Practice Database (GPRD)
    Zhang Bill, DeVries Frank, Setakis Efrosini, VanStaa Tjeerd.
    Pharmaco Drug Safety 2009: 18;S1-S273:594
  4. Initiation and persistence of warfarin or aspirin treatments in chronic atrial fibrillation: do the appropriatre patients receive stroke prophylaxis?
    Gallagher A, Rietbrock S, Plumb J, VanStaa T.
  5. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the General Practice Database.
    Gallagher A, Rietbrock S, Plumb J, VanStaa T.
  6. Chronic atrial fibrillation: incidence, Prevalence and prediction of stroke using the CHAD2 Risk stratification scheme.
    Gallagher AM, Rietbrock S, Heeley E, Plumb J, VanStaa T.
  7. The contribution and persistence and compliance with bisphosphonates on fracture outcomes.
    Rietbrock S, Olsen M, VanStaa TP.
  8. Benefit harm modelling: what is this and what can it contribute to pharmacovigilance?
    VanStaa T, Lynd LD, Leufkens Hubert GM, Raine J, Petri H.
  9. The pattern of risk of myocardial infarction in ptients taking asthma medication: A study with UK General Practice Database
    Zhang B, DeVries F, Setakis E Vanstaa TP
    Pharmaco Drug Safety 2009:18;S1-S273:481
  10. Assessment of Data Quality in Health Care Databases
    Juszczak, Williams T, VanStaa T,
    Pharmaco Drug Safety 2009:18::S1-S273:422
  11. Use of Dopaminergic Drugs and risk of hip or femur fracture: A population case-control study.
    Arbouw M, Movig K, Vanstaa T, deVries F et.a.
    Pharmaco Drug Safety 2009:18::S1-S273:464
  12. Methodological and Regulatory challenges in the Assessment of long term drug safety
    De Bruin ML, VanStaa TP, et al.
    Pharmaco Drug Safety 2009:18::S1-S273:397
  13. Evaluation of the level of anticoagulation control in patients with non-valvular atrial fibrillation
    Zhang,B, Setakis E, vanStaa TP
    Pharmaco Drug Safety 2009:18::S1-S273:265
  14. Use of proton pump inhibitors and risk of hip fracture
    Lalmohamed A, Pouwels S, Cooper C, VanStaa T, deVriesF, Leufkens B
    Pharmaco Drug Safety 2009:18::S1-S273:039
  15. Use of Organic nitrates and the risk of hip fracture: A population based case-control study
    Lalmohamed A, Pouwels S, Cooper C, VanStaa T, deVriesF, Leufkens B, et al
    Pharmaco Drug Safety 2009:18::S1-S273:018
  16. Risks of mortality and stroke associated with sub-optimally anticoagulated atrial fibrillation patients
    Setakis E, Zhang B, VanStaa TP
    Pharmaco Drug Safety 2009:18::S1-S273:509
  17. Insomnia as a predictor of depression in UK primary care
    de Vries F: Gallagher AM; Lader MH; Tylee AT; Donoghue J; Cockle SM; vanStaa TP, Nutt DJ.
    European Neuropsychopharmacology 2009(19)S372-S373
  18. Resource use in depressed patients with sleep disturbance
    Gallagher, AM; deVries F; Nutt DJ; Donoghue J; Tylee AT, Cockle SM; vanStaa TP; Lader MH.
    European Neuropsychopharmacology 2009(19)S 378-S379
  19. Initiation of hypnotics or anxiolytics in depressed patients with sleep disturbance
    Gallagher, AM; deVries F; Nutt DJ; Donoghue J; Tylee AT, Cockle SM; vanStaa TP; Lader MH.
    European Neuropsychopharmacology 2009(19)S379
  20. The risk of suicide and suicidal ideation in depressed patiens with sleep disturbance.
    Gallagher, AM; deVries F; Nutt DJ; Donoghue J; Tylee AT, Cockle SM; vanStaa TP; Lader MH.
    European Neuropsychopharmacology 2009(19)S380
  21. Persistance with hypnotics in depressed patients treated in UK primary care.
    Gallagher, AM; deVries F; Nutt DJ; Donoghue J; Tylee AT, Cockle SM; vanStaa TP; Lader MH.
    European Neuropsychopharmacology 2009(19)S381
  22. The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients.
    Hamilton W.
    British Journal of Cancer. 2009:S80 – S6.

Abstract & Posters - 2008

  1. Outcomes following a hip fracture and length of hospitalization
    De Vries F, Gallagher A, Ariely R, van Staa T.
    Pharmo
  2. Last menstrual period estimation techniques compared to physician recorded last menstrual period dates in the GPRD.
    Devine ST, Hammad TA.
    Pharmacoepidemiology & Drug Safety:2008;17:S228
  3. GPRD Study of pregnancy outcomes following the prescribing of DMARDs.
    Vroom F, Snowball J, McGrogan A, de Jong-van Berg L, deVries C.
    Pharmacoepidemiology & Drug Safety:2008;17:S227
  4. Changes in the characteristics of patients prescribed selective Cox-2 inhibitors after the 2004 withdrawal of Rofecoxib.
    Setakis E, Leufkens HGM, vanStaa T.
    Pharmacoepidemiology & Drug Safety:2008;17:S9
  5. The feasibility of linking the English Hospital Episode Statistics to the GPRD.
    Eaton SC, Williams TJ, Puri S, vanStaa T.
    Pharmacoepidemiology & Drug Safety:2008;17:S214
  6. Benefit-Harm Modelling: What is this and what can it contribute to Pharmacovigilance?
    Van Staa TP, Lynd LD, Leufkens GM, Raine J, Petri H.
  7. Effect of antibiotics for Otitis Media on mastoiditis in children: Retrospective Cohort Study using the UK GPRD.
    Thompson PL, Gilbert R, Long P, Saxena S, Sharland M, Wong I.
    Pharmacoepidemiology & Drug Safety:2008;17:S209
  8. Mortality following antiepileptic drugs in paediatrics with epilepsy – preliminary results using the GPRD.
    Ackers R, Besag FMC, Wong ICK,
    Pharmacoepidemiology & Drug Safety:2008;17:S9
  9. Outcomes evaluation following 12 month treatment with once daily tiotropium compared with four times daily Ipratropium/salbutamol: A GPRD study on patients with COPD.
    Griffin J. Lee S, Caiado M, Price D, Kesten S
    Pharmacoepidemiology & Drug Safety:2008;17:S183
  10. A review of Post-Marketing safety studies submitted to the UK Regulator from 1993-2005
    Shafe ACE, Wise L, Waller P.
    Pharmacoepidemiology & Drug Safety:2008;17:S179
  11. An analysis of glitazone use and small bone fractures using the GPRD database
    Irvine D, Wise L.
    Pharmacoepidemiology & Drug Safety:2008;17:S174
  12. Association between Alendronate Usage and Vitreous detachment: A cohort study.
    Shafe A CE, Wise L.
    Pharmacoepidemiology & Drug Safety:2008;17:S165
  13. The General Practice Research Database as a pregnancy registry system: Anticonvulsants as an example.
    Charlton R, Weil J, Cunnington M, deVries C.
    Pharmacoepidemiology & Drug Safety:2008;17:S159
  14. Fracture risk in patients receiving concomitant bisphosphonate and proton pump inhibitors or bisphosphonates alone: The UK General Practice Research Database.
    deVries F, Cooper A, Logan R, Cockle S, Cooper C, VanStaa TP.
    Pharmacoepidemiology & Drug Safety:2008;17:S151
  15. Validation of pregnancy identification algorithm within the GPRD.
    Devine ST, Hammad TA, Andrews EB.
    Pharmacoepidemiology & Drug Safety:2008;17:S126
  16. Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in the GPRD.
    Hennessy S, Leonard CE, Palumbo CM, Bilker WB, Newcomb C, Kimmell S.
    Pharmacoepidemiology & Drug Safety:2008;17:S86
  17. The contribution of persistence and compliance with bisphosphonates on fracture outcomes.
    Reitbrock S, Olson M, Vanstaa TP
    Pharmacoepidemiology & Drug Safety:2008;17:S78
  18. Chronic atrial fibrillation: Incidence, Prevalence and prediction of stroke using the CHADS2 risk stratification scheme.
    Gallagher, AM, Reitbrock S, Heeley E, Plumb J, Vanstaa TP.
    Pharmacoepidemiology & Drug Safety:2008;17:S31
  19. Exploring channelling bias of anti-epileptic drugs in epilepsy patients in a US claims database and a UK General Practice database.
    Ishihara-Paul L, Webb DJ, Juneja M, Kanakarja P, Weil J.
    Pharmacoepidemiology & Drug Safety:2008;17:S23
  20. Initiation and persistence of warfarin or aspirin treatments in chronic atrial fibrillation: Do the appropriate patients receive stroke prophylaxis?
    Gallagher AM, Reitbrock S, Plumb J, VanStaa TP.
    Pharmacoepidemiology & Drug Safety:2008;17:S11

  1. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
    Vanstaa T, Reitbrock S, Setakis E.
    Pharmacoepidemiology & Drug Safety:2008;17:S9
  2. Regional variations in joint replacement: disease or service provision?
    Culliford D, Maskell J, Mullee M, Arden N.
    British Society of Rheumatology (2008)
  3. Temporal changes in the trends of total and unicondylar knee replacements in the UK.
    Maskell J, Culliford D, Mullee M, Arden K.
    British Society of Rheumatology (2008)
  4. Antibiotic prescribing for otitis media in children in UK primary care: have the national guidelines affected GP prescribing practice?
    Thompson, P.L., Gilbert, R., Long, P.F., Saxena, S., Sharland, M and Wong, I.C.K.
    Pharmacoepidemiology and Drug Safety. 2008;17:S273.
  5. Do antibiotics for otitis media reduce the risk of mastoiditis in children?
    Thompson, P.L., Gilbert, R., Long, P., Saxena, S., Sharland, M and Wong, I.C.K.
    Archives of Disease in Childhood. 2008;93:A75.
  6. Do antibiotics for otitis media reduce the risk of mastoiditis in children?
    Thompson, P.L., Gilbert, R., Long, P., Saxena, S., Sharland, M and Wong, I.C.K.
    International Journal of Pharmacy Practice. 2008;16:A10.
  7. Effect of antibiotics for otitis media on mastoiditis in children: A retrospective cohort study using the UK General Practice Research database.
    Thompson, P.L., Gilbert, R., Long, P., Saxena, S., Sharland, M and Wong, I.C.K.
    Pharmacoepidemiology and Drug Safety. 2008;17:748.
  8. Emission inventory development for the Hong Kong special administrative region.
    Pollack A, Morris R, Yeung D, Sham P, Fung C, Leung K.
    Proceedings of the Air and Waste Management Association's Annual Conference and Exhibition, AWMA 2008; 7: 4393-4396.
  9. Supporting UK-wide e-clinical trials and studies.
    Stell A, Sinnott R, Ajayi O.
    ACM International Conference Proceeding Series, 2008; 320: art. no. 1341828.
  10. Discrimination of civilian vehicles using wide-angle SAR.
    Dungan KE, Potter LC, Blackaby J, Nehrbass J.
    Proceedings of SPIE - The International Society for Optical Engineering, 2008; 6970: art. no. 69700Z.

Abstract & Posters - 2007

  1. The effect of heart rate and it’s changes on cardiovascular disease and mortality.
    Setakis E, Williams TJ, van Staa TP
    Pharmacoepidemiology & Drug Safety (2007)
  2. Onset and offset of fracture benefit associated with bisphosphonate use.
    Gallagher AM, Rietbrock S, Olson M, Leufkens HGM, van Staa TP.
    Pharmacoepidemiology & Drug Safety (2007)
  3. The incidence of Wegener’s granulomatosis and Chrug Strauss syndrome in the UK General Practice Database
    Watts R, Al-Taiar A, Skinner J, Scott D, MacGregor A.
    American College of Rheumatology (2007)
  4. What are antibiotics being prescribed for in children, and how has this changed over time in UK general practice?
    Thompson, P.L., Gilbert, R., Long, P., Sharland, M. and Wong, I.C.K.
    International Journal of Pharmacy Practice. 2007;15:A24.
  5. Changes in antibiotic-resistance rates for invasive Haemophilus Influenzae isolates in England and Wales and their association with antibiotic prescribing in the community.
    Ladhani, S., Heath, P., Ramsay, M., Thompson, P., Sharland, M. and Slack, M.
    Archives of Disease in Childhood. 2007; 92:A80.
  6. What are antibiotics being prescribed for in children, and how has this changed over time in UK general practice?
    Thompson, P.L., Gilbert, R., Long, P., Sharland, M. and Wong, I.C.K.
    Archives of Disease in Childhood. 2007;92:A86
  7. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: Analysis conducted on the United Kingdom General Practitioner Research Database.
    Lafuma A, Berdeaux G.
    Current Medical Research and Opinion, 2007; 23(12): 3009-3016.
  8. The utility of the general practice research database to examine selected congenital heart defects - A validation study.
    Wurst, Keele E.; Ephross, Sara A.; Loehr, James; et al.
    Pharmacoepidemiology and Drug Safety. 2007;16:S131.
  9. Validation of neural tube defects in the general practice research database.
    Devine, Scott; West, Sue; Eaton, Susan; et al.
    Pharmacoepidemiology and Drug Safety. 2007;16:S130-S131.
  10. Validation of UK general practice research database mother-baby linkage using a sample of congenital heart defect records.
    Wurst, Keele E.; Ephross, Sara A.
    Pharmacoepidemiology and Drug Safety. 2007;16:S150.

Abstract & Posters - 2006

  1. Blood pressure lowering thresholds and stroke
    Qizilbash N, Mander A, Feudjo-Tepie M, Boudiaf N.
    Pharmacoepidemiology & Drug Safety (2006); 15: S271
  2. A time-trend analysis of all clinical activity, amoxicillin/co-amoxiclav prescribing, acute otitis media and acute mastoiditis in paediatrics in general practice.
    Thompson, P.L., Gilbert, R., Long, P., Murray. M.L., Sharland, M. and Wong, I.C.K.
    Pharmacoepidemiology and Drug Safety. 2006;15:S147-S148
  3. Prescription patterns of major antidepressant drugs in adults diagnosed with depression: A GPRD based study.
    Bineau, Sebastien; Saragoussi, Delphine; Despiegel, Nicolas; et al.
    Pharmacoepidemiology and Drug Safety. 2006;15:S163.
  4. Risk adjusted sequential and longitudinal monitoring drug performance using GPRD.
    Ma, Mark L.; Hornbuckle, Kenneth; Voss, Simon; et al.
    Pharmacoepidemiology and Drug Safety. 2006;15:S33.
  5. Verification of observational data using GPRD.
    Williams, Tim J.; Murray-Thomas, Tarita; Ambersley, Brendon.
    Pharmacoepidemiology and Drug Safety. 2006;15:S220.
  6. Use of oral glucocorticoids and risk of suicide: A cohort study in the general practice research database.
    Souverein, Patrick C.; Speksnijder, Niels; van Staa, Tjeerd P.; et al.
    Pharmacoepidemiology and Drug Safety. 2006;15:S3.

Abstract & Posters - 2005

  1. Use of the General Practice Research Database to detect drug-induced autoimmune disease.
    Schoonen WM, Somers EC, Hall AJ
    Pharmacoepidemiology & Drug Safety (2005); 14: S199
  2. A reanalysis of two studies that reported contrasting results on the association between statin use and risk of fracture in the same database.
    De Vries F, de Vries C, Cooper C, Leufkens H, van Staa TP
    Pharmacoepidemiology & Drug Safety (2005); 14: S199
  3. Use of antiepileptic drugs and risk of fractures: a case-control study among patients with epilepsy.
    Souverein PC, Webb DJ, Weil J, van Staa TP, Egberts TCG
    Pharmacoepidemiology & Drug Safety (2005); 14: S192-193
  4. Rates of serious vascular events among patients dispensed type 2 antidiabetic medications in the U.S. and U.K.
    Velentgas P, Cole JA, Costa L, Ziyadeh N, Shea K, Seeger JD, Walker AM
    Pharmacoepidemiology & Drug Safety (2005); 14: S173-174
  5. The risk of venous thromoboembolism associated with cyproterone acetate amongst men with advanced carcinoma of the prostate.
    Seaman H, Farmer RDT
    Pharmacoepidemiology & Drug Safety (2005); 14: S172
  6. Matched retrospective cohort study of breast cancer incidence among initiators of racemic zopiclone, temazepam, and zolpidem in the General Practice Research Database.
    Eng PM, Ziyadeh N, Nordstrom BL, Caron J, Amato D, Seeger JD
    Pharmacoepidemiology & Drug Safety (2005); 14: S162
  7. Changes in the prevalence and incidence of coronary heart disease in the UK between 1992 and 2001.
    Seaman H, Hutchinson A, Farmer RDT, de Vries CS
    Pharmacoepidemiology & Drug Safety (2005); 14: S155-156
  8. Characteristics of end stage renal disease patients receiving phosphate binder therapy in UK primary care.
    Gallagher AM, Elgazzar H, Hughes G
    Pharmacoepidemiology & Drug Safety (2005); 14: S145-146
  9. A novel methodology for measuring the influence of comorbidity in disease outcome studies.
    Kiri VA, Visik G, Muellerova H, MacKenzie G
    Pharmacoepidemiology & Drug Safety (2005); 14: S135-136
  10. Risk of fracture in patients using high-dose intermittent oral glucocorticoids.
    De Vries F, van Staa TP, Bracke M, Cooper C, Lammers JW, Leufkens H
    Pharmacoepidemiology & Drug Safety (2005); 14: S133-134
  11. The association between antiepileptic drug use and aplastic anaemia.
    Van den Bemt PMLA, Souverein PC, van Staa TP, Meyboom RHB, van Solinge WW, Egberts TCG, Leufkens BGM
    Pharmacoepidemiology & Drug Safety (2005); 14: S109
  12. Tranexamic acid, menorrhagia, and venous thromoboembolism: a case-control study using the GPRD.
    Sundstrom A, Seaman H, Alfredsson L
    Pharmacoepidemiology & Drug Safety (2005); 14: S108
  13. Risk factors for inflammatory bowel disease in the general population.
    Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA
    Pharmacoepidemiology & Drug Safety (2005); 14: S99-100
  14. Evaluation of prescribing to patients with coronary heart disease against the national service framework.
    Hutchinson A, Seaman H, Farmer R, de Vries C
    Pharmacoepidemiology & Drug Safety (2005); 14: S85-86
  15. Pneumonia in an asthma cohort in general practice in the UK.
    Garcia Rodriguez LA, Wallander MA, Johansson S, Ruigomez A
    Pharmacoepidemiology & Drug Safety (2005); 14: S97-98
  16. Demyelinating disorders are more common among patients with inflammatory bowel disease (IBD) even in the absence of anti-TNFα therapy.
    Gupta G, Gelfand JM, Lewis JD
    Pharmacoepidemiology & Drug Safety (2005); 14: S66
  17. Propensity score matching to identify cohorts of patients prescribed type 2 diabetes medications in the General Practioner Research Database.
    Cole JA, Velentgas P, Ziyadeh N, Costa L, Shea K, Seeger J, Walker AM
    Pharmacoepidemiology & Drug Safety (2005); 14: S62
  18. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population.
    Huerta C, Varas Lorenzo C, Castellsague J, Garcia Rodriguez LA
    Pharmacoepidemiology & Drug Safety (2005); 14: S59
  19. Depression and the underlying hazard of suicidal behavior.
    Rietbrock S, Martinez C
    Pharmacoepidemiology & Drug Safety (2005); 14: S55
  20. Trends in prescribing of methylphenidate in the UK.
    Williams TJ, Hughes G, Martinez C
    Pharmacoepidemiology & Drug Safety (2005); 14: S54-55

  1. Duration of therapy among patients dispensed type 2 diabetes medications in the U.S. and U.K.
    Velentgas P, Cole JA, Ziyadeh N, Costa L, Shea K, Seeger JD, Walker AM
    Pharmacoepidemiology & Drug Safety (2005); 14: S49
  2. Lymphoma risk in patients with rheumatoid arthritis who received 2 or more disease modifying antirheumatic drugs (DMARDs): a retrospective cohort study in the GPRD.
    Mines DI, Novelli LA, Yu H
    Pharmacoepidemiology & Drug Safety (2005); 14: S30
  3. New users of inhaled corticosteroids (ICS) in the United Kingdom have higher probability of continuous use than new users in the Netherlands.
    Menckeberg TT, Pokladnikova J, Bouvy ML, Belitser SV, Bracke M, Raaijmakers JAM, Leufkens HGM
    Pharmacoepidemiology & Drug Safety (2005); 14: S29
  4. Epidemiology and treatment patterns of psoriasis in the General Practice Research Database (GPRD).
    Gelfand JM, Wang X, Liu Q, Neiman A, Weinstein R, Margolis DJ, Troxel AB
    Pharmacoepidemiology & Drug Safety (2005); 14: S23-24
  5. Incidence of selected outcomes among matched cohorts of initiators of racemic zopiclone, temazepam, and zolpidem in the General Practice Research Database.
    Eng PM, Ziyadeh N, Nordstrom BL, Caron J, Amato D, Seeger JD
    Pharmacoepidemiology & Drug Safety (2005); 14: S22-23
  6. Use of beta-blockers and risk of hip and vertebral fracture: relationships to daily and cumulative dose.
    De Vries F, Souverein PC, De Bruin ML, Leufkens HGM, Cooper C, Van Staa TP
    Pharmacoepidemiology & Drug Safety (2005); 14: S21-22
  7. Prevalence of osteoarthritis and rheumatoid arthritis: cross-sectional analysis in a follow-up study.
    Gonzalez-Perez A, Garcia Rodriguez LA, Johansson s, Wallander MA
    Pharmacoepidemiology & Drug Safety (2005); 14: S7-8

Abstract & Posters - 2004

  1. The risk of first seizure associated with mefenamic acid in women of reproductive age
    Mines DI, Novelli LA
    Pharmacoepidemiology & Drug Safety (2004) 13: S333-4
  2. Natural history of dyspepsia in general practice: incidence, comorbidity and risk factors
    Ruigomez A, Wallander MA, Johannson, Garcia Rodriquez LA
    Pharmacoepidemiology & Drug Safety (2004) 13: S309
  3. Natural history of chest pain in general practice setting
    Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA
    Pharmacoepidemiology & Drug Safety (2004) 13: S308-9
  4. Estimating annual prevalence of clinically-significant psoriasis in the General Practice Research Database (GPRD)
    Crane MM, Hastie JM, Black CL
    Pharmacoepidemiology & Drug Safety (2004) 13: S306-7
  5. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the UK
    Cavazzoni P, Hornbuckle K, Carlson C, DeLisle F, Noel R, Breier A
    Pharmacoepidemiology & Drug Safety (2004) 13: S304
  6. Increased rates of diagnosis for hypertension or dyslipidaemia in patients previously identified with one of these risk factors: data from the United Kingdom
    MacDonald TM, Morant SV, Mozaffari E
    Pharmacoepidemiology & Drug Safety (2004) 13: S302-3
  7. The risk of venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol - an update
    Seaman HE, de Vries CS, Farmer RDT
    Pharmacoepidemiology & Drug Safety (2004) 13: S275
  8. Cross-over cohort study of incident VTE in women exposed to cyproterone in UK primary care
    Moseley JNS
    Pharmacoepidemiology & Drug Safety (2004) 13: S274-5
  9. Treatment patterns for hypertension, dyslipidaemia, and both conditions in the United Kingdom: 1997-2001
    MacDonald TM, Morant SV, Baker CL, Mozaffari E
    Pharmacoepidemiology & Drug Safety (2004) 13: S237-8
  10. Systemic lupus erythematosus: calculating the prevalence of relapsing-remitting disease using left-censored data
    Nightingale AL, de Vries CS, Farmer RDT
    Pharmacoepidemiology & Drug Safety (2004) 13: S230
  11. Measuring incidence rates using GPRD: how soon after registration do incidence rates reach baseline levels?
    Lewis JD, Bilker WB, Weinstein R, Strom BL
    Pharmacoepidemiology & Drug Safety (2004) 13: S230-1
  12. Methodological issues in determining daily hormonal contraceptive exposure on the General Practice Research Database
    Snowball JM, Farmer RDT
    Pharmacoepidemiology & Drug Safety (2004) 13: S157-8
  13. Medications prescribed before and during early pregnancy in a cohort of 81 975 mother-baby pairs: a population based study using the automated data of the General Practice Research Database
    Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB
    Pharmacoepidemiology & Drug Safety (2004) 13: S138-9
  14. First use of oral contraceptives before and after the pill scare in the UK
    Farmer RD, de Vries CS, Seaman HE
    Pharmacoepidemiology & Drug Safety (2004) 13: S138
  15. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation (AF) treated with warfarin
    Gasse C, Hollowell J, Meier CR, Troost J, Schneider V, Haefeli WE
    Pharmacoepidemiology & Drug Safety (2004) 13: S134-5
  16. Survival analysis to examine the risk of a recurrent stroke of patients in the General Practice Research Database
    Short D, Chapman S
    Pharmacoepidemiology & Drug Safety (2004) 13: S134
  17. The increasing proportion of patients with type 2 diabetes converting to insulin therapy in the UK
    Mulnier H, Lovell D, Lawrenson R
    Pharmacoepidemiology & Drug Safety (2004) 13: S129
  18. Predicting cardiac arrhythmias and sudden death among diabetic users of arrhythmogenic non-antiarrhythmic drugs
    De Bruin ML, van Staa TP, Belitser SV, Leufkens HGM, Hoes AW
    Pharmacoepidemiology & Drug Safety (2004) 13: S124
  19. In-utero exposure to antihistamines and the risk of congenital hypospadias or cryptorchidism in male births
    Williams T, Hughes G, Martinez C
    Pharmacoepidemiology & Drug Safety (2004) 13: S126
  20. Adverse drug reaction profiles for fluoxetine, paroextine and amitriptyline using data recorded by general practitioners in the United Kingdom (UK)
    Davis S, Rietbrock S, Martinez C
    Pharmacoepidemiology & Drug Safety (2004) 13: S118-9

  1. Treatment of high-risk hypertensive patients in the United Kingdom: 1997-2001
    MacDonald TM, Morant SV, Baker CL, Mozaffari E
    Pharmacoepidemiology & Drug Safety (2004) 13: S103
  2. Sudden unexpected death (SUDEP) in children and adolescents with epilepsy
    Hsia Y, de Vries CS
    Pharmacoepidemiology & Drug Safety (2004) 13: S83
  3. The risk of upper gastrointestinal tract bleeding associeated with mefenamic acid in women of reproductive age
    Mines DI, Novelli LA
    Pharmacoepidemiology & Drug Safety (2004) 13: S54-55
  4. The incidence of ventricular fibrillation and ventricular tachycardia in a primary care population
    Hughes G, Rietbrock S, Reiter C, Martinez C
    Pharmacoepidemiology & Drug Safety (2004) 13: S48
  5. A systematic approach for describing comorbidities using the UK General Practice Research Database
    Roskell NS, Logie JW, Stender M, Feudjo-Tepie M
    Pharmacoepidemiology & Drug Safety (2004) 13: S42
  6. An algorithm to extract medical codes for diagnoses from unstructured free text recorded by general practitioners in the UK
    Shah AD, Martinez C
    Pharmacoepidemiology & Drug Safety (2004) 13: S41-2
  7. Validity of the General Practice Research Database: a systematic review
    Schoonen WM, Hall AJ
    Pharmacoepidemiology & Drug Safety (2004) 13: S41
  8. Low treatment rates and poor goal attainment in patients with concomitant hypertension and dsylipidaemia: data from the United Kingdom
    MacDonald TM, Morant SV, Baker CL, Mozaffari E
    Pharmacoepidemiology & Drug Safety (2004) 13: S29-30
  9. Acute and long-term risk of femur fractures in patients on antipsychotics
    Hugenholz GWK, Heerdink ER, Nolen WA, Egberts TCG
    Pharmacoepidemiology & Drug Safety (2004) 13: S21-2
  10. Is there cross-reactivity between penicillins and cephalosporins? Investigaion of a large electronic medical record database.
    Apter AJ, Kinman JL, Milker WB, Herlin M, Margolis DJ, Lautenbach E, Hennessy S, Strom BL
    Pharmacoepidemiology & Drug Safety (2004) 13: S18
  11. The effect of selective serotonin reuptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression
    Kimmel SE, Berlin JA, Oslin DW, Weinstein RB, Kinman JL, Sauer WH, Lewis JD
    Pharmacoepidemiology & Drug Safety (2004) 13: S6
  12. Use of oral steroids and the risk of acute myocardial infarction in the U.K.
    Varas-Lorenzo C, Garcia-Rodriguez LA, Maguire A, Perez-Gutthann S
    Pharmacoepidemiology & Drug Safety (2004) 13: S5-6
  13. A comparison of the cause of death recorded in the General Practice Research Database with national mortality statistics in England and Wales
    Shah AD, Martinez C
    Pharmacoepidemiology & Drug Safety (2004) 13: S2-3

Abstract & Posters - 2003

  1. The 'Drug Allergy and Intolerance' Structured Data Area: an additional information source of suspected Adverse Drug Reactions (ADRs) in the Full Feature General Practice Research Database
    Martinez C, Davis S, Heeley E, Moseley J, Rietbrock S.
    Pharmacoepidemiol and Drug Safety (2003); 12: S244
  2. Auditing the quality of data in the General Practice Research Database
    Davis S, Rietbrock S, Rubino A, Shah AD, Williams T, Martinez C.
    Pharmacoepidemiol and Drug Safety (2003); 12: S61
  3. An algorithm to derive a numerical daily dose from text dosage instructions in the General Practice Research Database
    Shah AD, Martinez C.
    Pharmacoepidemiol and Drug Safety (2003); 12: S60-61
  4. Impact of Therapy Used in Clinical Practice on Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Disease Progression.
    Berges R.
    European Urology, 2003; Supplement 2(7): 19-24.

Abstract & Posters - 2002

  1. Linkage of Socio-Economic Status data to the General Practice Research Database
    Williams TJ, Martinez C
    Pharmacoepidemiology & Drug Safety (2002) 11: S168
  2. Validation of birth recording and development of a mother-baby link in the FF-GPRD
    Rubino A
    Pharmacoepidemiology & Drug Safety (2002) 11: S70-71
  3. Cardiovascular outcomes in hypertensives treated with ACE inhibitors or calcium channel blockers differ: Evidence from UK General Practice Research Database.
    McInnes, Gordon T.; Hole, David J.; Murray, Lilian S.; et al.
    Circulation. 2002;106(19 Supplement):574-575.

Abstract & Posters - 2000

  1. How do symptoms indicative of BPH progress in real life practice? The UK experience.
    Clifford GM, Logie J, Farmer RDT.
    European Urology, 2000; 38(SUPPL. 1): 48-53.
  2. What is the impact of differential follow-up time on studies of disease burden in the General Practice Research Database?
    Eaton S, McQuay L, Clark D.
    Pharmacoepidemiol Drug Safety. 2000;9(Supplement 1):S144-S145.
  3. Upper gastrointestinal complications associated with use of non-steroidal anti-inflammatory drugs according to the nature of the outcome.
    Hernandez-Diaz, Sonia; Garcia-Rodriguez, Luis A.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S67.
  4. Trends in ACE inhibitor prescribing in general practice (1993-1997): An investigation using the General Practice Research Database.
    Heatlie, Heath F.; Norwood, Jeff; Bashford, James.
    Pharmacoepidemiology and Drug Safety. 2000:9(Supplement 1):S7.
  5. The treatment of Bell's palsy in general practice.
    Rowlands, Sam; Hughes, Richard A. C.; Burney, Peter; et al.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S33.
  6. The risk of liver injury associated with minocycline.
    Seaman, Helen E.; Lawrenson, Ross A.; Williams, Tim J.; et al.
    Pharmacoepidemiology and Drug Safety. 2000:9(Supplement 1):S47.
  7. Selective serotonin reuptake inhibitors (SSRIs) and acute myocardial infarction (AMI).
    Meier, Christoph R.; Schlienger, Raymond G.; Jick, Hershel.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S10.
  8. Prevalence of asthma by severity in the general population.
    Heatlie, Heath F.; Frischer, Martin; Clark, Wendy.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S26-S27.
  9. Prevalence and incidence of diagnosed allergic rhinitis in the UK general and asthmatic populations.
    Castellsague, Jordi; Garcia Rodriguez, Luis Alberto.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S82-S83.
  10. Patterns of prescribing of hormonal emergency contraception by general practitioners in England and Wales.
    Ineichen, Berhard; Logie, John W.; Rowlands, Sam; et al.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S56-S57.
  11. Patterns of Hormone Replacement Therapy in the UK.
    Causier, Susan E.; de Vries, Corinne S.; Williams, Tim J.; et al.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S130.
  12. Initial therapy of inflammatory bowel disease (IBD) in the United Kingdom.
    Lewis, James D.; Bilker, Warren B.; Brensinger, Colleen; et al.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S17-S18.
  13. Incidence of ocular melanoma in the general population and glaucoma patients.
    Huerta, Consuelo; Garcia Rodriguez, Luis Alberto.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S8.
  14. Incidence of newly diagnosed heart failure in general practice.
    Johannson, Saga; Wallander, Mari-Ann; Ruigomez, Ana; et al.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S13.
  15. A study of antibiotic resistance in women treated for urinary tract infections.
    Logie, John W.; Lawrenson, Ross A.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S56.
  16. Antidepressant exposure and the risk of hip fractures: A case-control study using the UK general practice research database (GPRD).
    Hubbard, Richard; Smeeth, Liam; Smith, Chris; et al.
    Pharmacoepidemiology and Drug Safety. 2000;9(Supplement 1):S38.
  17. Venous thromboembolism and combined oral contraceptives: Does the type of progestogen make a difference?
    Lawrenson R, Farmer R.
    Contraception, 2000; 62(2 SUPPL. 1): S21-S28.

Abstract & Posters - 1998

  1. The epidemiology and medical care usage of patients with hepatitis B in a British population: The General Practice Research Database.
    Rosenberg DM, Cook SF, Eaton, S.
    Hepatology. 1998;28(4):232A.
  2. Ocular events among users of inhaled and oral corticosteroids.
    Jick SS, Maier WC.
    Eur Respir J. 1998;12(Supplement 29):82s.

Abstract & Posters - 1997

  1. Increased medical utilization among a random sample of irritable bowel syndrome (IBS) sufferers compared to matched controls using 1995 data from the general practice research database (GPRD).
    Saunders W, Vasilakis C.
    Am J Epidemiol. 1997;145(11 SUPPL):S9